Weekly Nephrology/Health IT News Roundup: October 22, 2010

Print This Post Print This Post

FDA May Limit Anemia Drug Use For Kidney Disease
The FDA posted its safety review of the three blood-boosting medications from Amgen Inc. – Procrit, Aranesp and Epogen – and is considering new restrictions on the widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease.

 

FDA Panel Backs Anemia Drugs For Kidney Disease
Officials vote 15-1 on Monday that patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

 

AAO: Vitamin D Has Retinopathy Link
A recent study of 123 diabetic individuals with varying degrees of retinopathy showed that low vitamin D levels were significantly more common in those with the diabetic complication.

 

Do We Need to Abandon High Ultrafiltration Rates in America?
Are dialysis practices to blame for our higher dialysis mortality?

 

A Buff Body Boosts Survival on Dialysis
For patients on maintenance hemodialysis, a recent study showed increasing mid-arm muscle circumference -– a surrogate for lean body mass – was associated with better five-year survival, as well as mental health.

Leave a Reply

Your email address will not be published. Required fields are marked *